|
|
 | | | |
- close
- close
- close
- close
| |||||||||
This excerpt taken from the ELN 6-K filed Aug 28, 2009. Interest
Expense
In the first half of 2009, interest expense amounted to
$71.4 million, compared to $75.1 million in the same
period of 2008. The decrease was primarily due to reduced
interest rates related to our floating rate notes, partially
offset by an increase in net foreign exchange losses.
This excerpt taken from the ELN 6-K filed Mar 30, 2009. b Interest
expense
This excerpt taken from the ELN 6-K filed Mar 31, 2008. d Interest
expense
This excerpt taken from the ELN 6-K filed Mar 30, 2007. d Interest
expense
This excerpt taken from the ELN 6-K filed Mar 31, 2006. Interest Expense
Interest expense was $179.3 million for 2005, compared to
$153.9 million for 2004. The increase primarily reflects
the full year interest costs associated with the issuance of
$850.0 million of 7.75% senior fixed rate notes
(7.75% Notes) and $300.0 million of senior floating
rate notes (Floating Rate Notes) in November 2004, partially
offset by the impact of the repayment of the Elan Pharmaceutical
Investments II, Ltd. issued guaranteed loan notes (EPIL II
Notes) in June 2004 and the Elan Pharmaceutical
Investments III Ltd. (EPIL III) Series B and C
guaranteed notes (collectively, the EPIL III Notes) in
November 2004, the early retirement of $36.8 million of the
7.25% Senior Notes (Athena Notes) due in 2008 and the early
conversion of $206.0 million in aggregate principal amount
of 6.5% Convertible Notes due in 2008 in the second quarter
of 2005.
| EXCERPTS ON THIS PAGE:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||
